Receptor tyrosine-protein kinase erbB-2 is aprotein that normally resides in the membranes of cells and is encoded by theERBB2gene. ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome. The human protein is also frequently referred to asHER2 (human epidermal growth factor receptor 2) orCD340 (cluster of differentiation 340).[5][6][7]
HER2 is a member of the humanepidermal growth factor receptor (HER/EGFR/ERBB) family. But contrary to other members of the ERBB family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer.[8]Amplification or over-expression of thisoncogene has been shown to play an important role in the development and progression of certain aggressive types ofbreast cancer. In recent years the protein has become an importantbiomarker and target of therapy for approximately 30% ofbreast cancer patients.[9]
HER2 is named as such due to structural similarities with human epidermal growth factor receptor 1, orHER1.
TheNeu alias of HER2 derives its name from the parentglioblastoma cell line - a type ofneural tumor found in rodents.
ErbB-2 was named for its similarity to avian erythroblastosis oncogene B, ErbB; theoncogene later shown to code for epidermal growth factor receptor,EGFR.
Molecular cloning of EGFR discovered that HER2, Neu, and ErbB-2 are all encoded by the sameorthologs.[10]
TheErbB family consists of four individualplasma membrane-boundreceptor tyrosine kinases. One of which is erbB-2, and the other members beingerbB-1,erbB-3 (neuregulin-binding; lacks kinase domain), anderbB-4. All four contain an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity. Notably, no ligands for HER2 have yet been identified.[13][14] HER2 can heterodimerise with any of the other three receptors and is considered to be the preferred dimerisation partner of the other ErbB receptors.[15]
Dimerisation results in theautophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors and initiates a variety of signaling pathways.
In summary, signaling through the ErbB family of receptors promotes cell proliferation and opposesapoptosis, and therefore must be tightly regulated to prevent uncontrolled cell growth from occurring.
Amplification, also known as the over-expression of theERBB2 gene, occurs in approximately 15-30% ofbreast cancers.[9][17] HER2-positive breast cancers are well established as being associated with increased disease recurrence and a poor prognosis compared with other identifiably genetically distinct breast cancers with other known, or lack thereof, genetic markers that are thought to be associated with other breast cancers; however, drug agents targeting HER2 in breast cancer have significantly and positively altered the otherwise poor prognosis of the historically problematic difficulties associated with HER2-positive breast cancer.[18] Over-expression is also known to occur in ovarian,[19] stomach,adenocarcinoma of the lung[20] and aggressive forms of uterine cancer, such as uterine serousendometrial carcinoma,[21][22] e.g. HER2 is over-expressed in approximately 7-34% of patients with gastric cancer[23][24] and in 30% of salivary duct carcinomas.[25]
HER2 is colocalised and most of the time, coamplified with the geneGRB7, which is a proto-oncogene associated with breast, testicular germ cell, gastric, and esophageal tumours.
HER2 proteins have been shown to form clusters in cell membranes that may play a role in tumorigenesis.[26][27]
Evidence has also implicated HER2 signaling in resistance to theEGFR-targeted cancer drugcetuximab.[28]
The high expression of HER2 correlates with better survival in esophageal adenocarcinoma.[29]
The high amplification of HER2 copy number positively contributes to the survival time of gastric cardia adenocarcinoma patients.[30]
Furthermore, diverse structural alterations have been identified that cause ligand-independent firing of this receptor, doing so in the absence of receptor over-expression. HER2 is found in a variety of tumours and some of these tumours carry point mutations in the sequence specifying the transmembrane domain of HER2. Substitution of a valine for a glutamic acid or a glutamine in the transmembrane domain can result in the constitutive dimerisation of this protein in the absence of a ligand.[31]
HER2 is the target of themonoclonal antibodytrastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy.[33] Randomized trials have demonstrated no additional benefit beyond 12 months, whereas 6 months has been shown to be inferior to 12. Trastuzumab is administered intravenously weekly or every 3 weeks.[34]
An important downstream effect of trastuzumab binding to HER2 is an increase inp27, a protein that halts cell proliferation.[35] Another monoclonal antibody,Pertuzumab, which inhibits dimerisation of HER2 and HER3 receptors, was approved by the FDA for use in combination with trastuzumab in June 2012.
As of November 2015, there are a number of ongoing and recently completed clinical trials of novel targeted agents for HER2+ metastatic breast cancer, e.g.margetuximab.[36]
Additionally,NeuVax (Galena Biopharma) is a peptide-based immunotherapy that directs "killer"T cells to target and destroy cancer cells that express HER2. It has entered phase 3 clinical trials.
It has been found that patients with ER+ (estrogen receptor positive)/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit thePI3K/AKT molecular pathway.[37]
Over-expression of HER2 can also be suppressed by the amplification of other genes. Research is currently being conducted to discover which genes may have this desired effect.
The expression of HER2 is regulated by signaling through estrogen receptors. Normally,estradiol andtamoxifen acting through the estrogen receptor down-regulate the expression of HER2. However, when the ratio of thecoactivatorAIB-3 exceeds that of thecorepressorPAX2, the expression of HER2 is upregulated in the presence of tamoxifen, leading to tamoxifen-resistantbreast cancer.[38][39]
HER2 testing is performed onbreast biopsy of breast cancer patients to assess prognosis and to determine suitability for trastuzumab therapy. It is important that trastuzumab is restricted to HER2-positive individuals as it is expensive and has been associated with cardiac toxicity.[41] For HER2-positive tumors, the benefits of trastuzumab clearly outweigh the risks.
Immunohistochemistry (IHC) is generally used to measure the amount of HER2 protein present in the sample, withfluorescence in situ hybridisation (FISH) being used on samples that are equivocal in IHC. However, in several locations, FISH is used initially, followed by IHC in equivocal cases.[42]
FISH can be used to measure the number of copies of the gene which are present and is thought to be more reliable than immunohistochemistry.[47] It usually useschromosome enumeration probe 17 (CEP17) to count the amount of chromosomes. Hence, the HER2/CEP17 ratio reflects any amplification of HER2 as compared to the number of chromosomes. The signals of 20 cells are usually counted.
This cell displays 2 signals of HER2 (red) and 3 signals of CEP17 (green)
Two signals that are closer to each other than the signal diameter count as one.
One of these signals is too faint, and is presumably debris.
Cells with only one type of signal are excluded from the count.
Overlapping cells are also excluded from the count.
A yellow signal counts as one red and one green (which are overlapping)
If the initial HER2 result is negative for a needle biopsy of a primary breast cancer, a new HER2 test may be performed on the subsequent breast excision.[48]
The extracellular domain of HER2 can be shed from the surface of tumour cells and enter the circulation. Measurement of serum HER2 by enzyme-linked immunosorbent assay (ELISA) offers a far less invasive method of determining HER2 status than a biopsy and consequently has been extensively investigated. Results so far have suggested that changes in serum HER2 concentrations may be useful in predicting response to trastuzumab therapy.[49] However, its ability to determine eligibility for trastuzumab therapy is less clear.[50]
^Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. (December 1985). "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene".Science.230 (4730):1132–1139.Bibcode:1985Sci...230.1132C.doi:10.1126/science.2999974.PMID2999974.
^Burstein HJ (October 2005). "The distinctive nature of HER2-positive breast cancers".The New England Journal of Medicine.353 (16):1652–1654.doi:10.1056/NEJMp058197.PMID16236735.S2CID26675265.
^Buza N, Roque DM, Santin AD (March 2014). "HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges".Archives of Pathology & Laboratory Medicine.138 (3):343–350.doi:10.5858/arpa.2012-0416-RA.PMID24576030.
^Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, et al. (June 2015). "Molecular characterization of apocrine salivary duct carcinoma".The American Journal of Surgical Pathology.39 (6):744–752.doi:10.1097/PAS.0000000000000410.PMID25723113.S2CID34106002.
^Kaufmann R, Müller P, Hildenbrand G, Hausmann M, Cremer C (April 2011). "Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy".Journal of Microscopy.242 (1):46–54.doi:10.1111/j.1365-2818.2010.03436.x.PMID21118230.S2CID2119158.
^Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. (June 2013). "Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives".Journal of Clinical Oncology.31 (16):1997–2003.doi:10.1200/JCO.2012.45.6095.PMID23610105.S2CID37663670.
^Telli ML, Hunt SA, Carlson RW, Guardino AE (August 2007). "Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility".Journal of Clinical Oncology.25 (23):3525–3533.doi:10.1200/JCO.2007.11.0106.PMID17687157.
^Giuliano AE, Hurvitz SA (2019). "Breast Disorder". In Papadakis MA, McPhee SJ, Rabow MW (eds.).Current Medical Diagnosis & Treatment. New York, NY: McGraw-Hill.
^Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, et al. (September 2008). "Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer".Cancer.113 (6):1294–1301.doi:10.1002/cncr.23689.PMID18661530.S2CID7307111.
^Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. (April 2009). "Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer".Journal of Clinical Oncology.27 (10):1685–1693.doi:10.1200/JCO.2008.16.8351.PMID19255335.
^Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, et al. (February 2001). "Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription".Cancer Research.61 (4):1671–1677.PMID11245482.
^Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, et al. (March 1995). "c-erbB-2 gene product directly associates with beta-catenin and plakoglobin".Biochemical and Biophysical Research Communications.208 (3):1067–1072.Bibcode:1995BBRC..208.1067K.doi:10.1006/bbrc.1995.1443.PMID7702605.
^Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, et al. (January 2002). "An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells".Oncogene.21 (3):460–474.doi:10.1038/sj.onc.1205100.PMID11821958.S2CID19754641.
^Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, et al. (August 2003). "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein".Molecular Cancer Research.1 (10):765–775.PMID12939402.
Zhou BP, Hung MC (October 2003). "Dysregulation of cellular signaling by HER2/neu in breast cancer".Seminars in Oncology.30 (5 Suppl 16):38–48.doi:10.1053/j.seminoncol.2003.08.006.PMID14613025.
Laudadio J, Quigley DI, Tubbs R, Wolff DJ (January 2007). "HER2 testing: a review of detection methodologies and their clinical performance".Expert Review of Molecular Diagnostics.7 (1):53–64.doi:10.1586/14737159.7.1.53.PMID17187484.S2CID9971746.
![Algorithm for the evaluation of HER2 on fluorescence in situ hybridization (FISH).[48]](/mt/?noimg=&dark=on&url=https%3a%2f%2fen.wikipedia.org%2fwiki%2fFile%3aHER2_FISH_algorithm.svg)
